ArticleLangenbeck's archives of surgery2026
ERAS enables safe ≤ 100-hour discharge after pancreatoduodenectomy: a multicenter cohort study.
Article in Langenbeck's archives of surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05192044 (Less Than 100 Hours Hospital Stay After Pancreatico-duodenectomy, RCT), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Less Than 100 Hours Hospital Stay After Pancreatico-duodenectomy, RCT
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEnhanced Recovery After Surgery (ERAS) pathways have been increasingly adopted in gastrointestinal surgery; however, their application to pancreatoduodenectomy (PD) remains variable due to concerns regarding postoperative morbidity and safety (1-3). This study aimed to evaluate the impact of ERAS on postoperative outcomes and the feasibility of ultra-early discharge following PD.
methodsA multicenter cohort study was conducted including 180 patients undergoing PD across four tertiary hepatopancreatobiliary centers. Sixty patients were managed prospectively under a standardized ERAS protocol, while 120 patients treated prior to ERAS implementation served as controls. Postoperative outcomes, including pancreatic fistula and delayed gastric emptying defined according to established criteria, were analyzed (4,5). Multivariate logistic regression was performed to identify predictors of discharge within ≤ 100 h.
resultsBaseline characteristics were comparable between groups. ERAS compliance exceeded 83% across key perioperative domains. Rates of clinically relevant pancreatic fistula were similar between groups (3.3% vs. 2.5%, p > 0.05). Delayed gastric emptying was significantly reduced in the ERAS cohort (13.3% vs. 31.7%, p = 0.011). Major complications (Clavien-Dindo ≥ III) occurred in 3.3% vs. 5.8%, readmission rates were 7.0% vs. 6.0%, and 90-day mortality was 3.3% vs. 1.7% in the ERAS and control groups, respectively. Mean length of stay was significantly shorter in the ERAS group (4.48 vs 10.91 days, respectively; p < 0.001), with 81.7% of patients achieving discharge within ≤100 hours compared to none in the control group. Importantly, while the majority of ERAS patients achieved early discharge, a small subset experienced prolonged hospital stay, resulting in partial overlap with the control group. ERAS implementation was the strongest independent predictor of early discharge.
conclusionERAS pathways in pancreatoduodenectomy are safe and reproducible, and enable substantial acceleration of postoperative recovery without increasing morbidity, supporting their integration into routine pancreatic surgical practice.
trial registrationClinicalTrials.gov Identifier: NCT05192044.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.